Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
Author:
Affiliation:
1. Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel
2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; Israel
Funder
No funding
Publisher
Informa UK Limited
Subject
Oncology,Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1959979
Reference23 articles.
1. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)
2. Improved local control with higher doses of radiation in large-volume stage III non–small-cell lung cancer
3. Potential of Adaptive Radiotherapy to Escalate the Radiation Dose in Combined Radiochemotherapy for Locally Advanced Non–Small Cell Lung Cancer
4. A Randomized Study of Involved-Field Irradiation Versus Elective Nodal Irradiation in Combination With Concurrent Chemotherapy for Inoperable Stage III Nonsmall Cell Lung Cancer
5. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ImmunoChemoradiation for Non-Small Cell Lung Cancer: A Meta-Analysis of Factors Influencing Survival Benefit in Combination Trials;International Journal of Radiation Oncology*Biology*Physics;2024-10
2. Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer;Radiotherapy and Oncology;2024-09
3. Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR);Radiotherapy and Oncology;2024-07
4. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;International Journal of Radiation Oncology*Biology*Physics;2024-07
5. Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis;Oncology Letters;2024-04-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3